



Fee Transmittal & Extension

FEE AUTHORIZATION/AMENDMENT TRANSMITTAL LETTER				Attorney's Docket No: SYNE-225-E (SYNE225/C4-US)		
Serial No. 08/182,183	Filing Date May 23, 1994	Examiner Marianne P. Allen	Group Art Unit 1812			
In Re Application of Lin et al. for GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR						
TO THE ASSISTANT COMMISSIONER OF PATENTS:						
<input checked="" type="checkbox"/> Applicant(s) petition(s) for the following extension of time under 37 C.F.R. 1.136(a):						
<input checked="" type="checkbox"/> One month of original due date (\$110.00) <input type="checkbox"/> Two months of original due date (\$370.00) <input type="checkbox"/> Three months of original due date (\$870.00) <input type="checkbox"/> Four months of original due date (\$1,360.00)						
<input checked="" type="checkbox"/> A response in connection with the matter for which this extension is requested:						
<input checked="" type="checkbox"/> is filed herewith. <input type="checkbox"/> has been filed. <input type="checkbox"/> The response is the filing of a continuation application having an express abandonment conditioned on the granting of a filing date to the continuing application.						
<input checked="" type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required. <input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:						
<b>CLAIMS AS AMENDED</b>						
(1)	(2) Claims remaining after amendment	(3)	(4) Highest number previously paid for	(5) No. of extra claims present	(6) Rate	(7) Additional Fee
Total Claims	39	Minus	74 =	0	x \$22 =	0
Indep. Claims	5	Minus	15 =	0	x \$76 =	0
Total Additional Fee for this Amendment						
*If the entry in column 2 is less than the entry in column 4, write "0" in column 5. **If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space. ***If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.						
<input type="checkbox"/> The following other fees are incurred by the accompanying papers. <input type="checkbox"/>						
Please charge Deposit Account No. 01-0519 in the name of Amgen Inc. in the amount of \$ <u>110.00</u> . A duplicate copy of this petition is attached.						
<input checked="" type="checkbox"/> If an additional extension of time is required, please consider this a petition therefore. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 01-0519.						
<u>Please Send Future Correspondence To:</u> U.S. Patent Operations/DRC M/S 10-1-B AMGEN INC. Amgen Center 1840 Dehavilland Drive Thousand Oaks, California 91320-1789						
 Daniel R. Curry Attorney for Applicants Registration No.: 32,727 Phone: (805) 447-8102 Date: January 5, 1996						

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231, on the date appearing below.

January 5, 1996

  
Nola J. Wyer

Date

Pull to Open

Pull to Open

RECYCLABLE

**AMGEN**

Amgen Center  
1840 Dehavilland Drive  
Thousand Oaks  
California 91320-1789

Inventors Names: Lin et al.  
Invention Title: GLIAL CELL LINE-DERIVED  
NEUROTROPHIC FACTOR  
Filing Date: May 23, 1994  
Serial No.: 08/182,183  
Date Listing Prepared: January 3, 1996  
Docket No.: SYNE-225-E

MACINTOSH OPERATING SYSTEM 7.1/Microsoft Word 5.1a

Patentin Release 1.0 ver. I.25

**CAUTION**  
**FLOPPY DISK ENCLOSED**

Do not bend or fold  
AVOID EXPOSURE TO ALL MAGNETIC FIELDS

Inventors Names: Lin et al.  
Invention Title: GLIAL CELL LINE-DERIVED  
NEUROTROPHIC FACTOR  
Filing Date: May 23, 1994  
Serial No.: 08/182,183  
Date Listing Prepared: January 3, 1996  
Docket No.: SYNE-225-E

MACINTOSH OPERATING SYSTEM 7.1/Microsoft Word 5.1a

Patentin Release 1.0 ver. I.25

*oy to Dept H  
1/30/96*

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE  
RECEIPT OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND  
RETURNING THIS POST CARD

Docket No.: **SYNE-225E** USSSN: **08/182,183** Filed: **5/23/94**

Inventors: **Lin et al.**

Title: **GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR**

**Including:**

- 1 page Transmittal Letter w/ 1 copy
- 15 pages Response
- 1 computer readable disk containing sequence listing
- 12 pages sequence listing in written form
- 1 page Attorney Statement re: sequence listing
- 1 page Fee Transmittal and Extension of Time

DRC:n FIRST CLASS MAIL *January 5, 1996* by njw

THE PATENT OFFICE IS HEREBY REQUESTED TO ACKNOWLEDGE  
RECEIPT OF THE FOLLOWING DOCUMENTS BY DATE STAMPING AND  
RETURNING THIS POST CARD

Docket No.: **SYNE-225E** USSSN: **08/182,183** Filed: **5/23/94**

Inventors: **Lin et al.**

Title: **GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR**

**Including:**

- 1 page Transmittal Letter w/ 1 copy
- 15 pages Response
- 1 computer readable disk containing sequence listing
- 12 pages sequence listing in written form
- 1 page Attorney Statement re: sequence listing
- 1 page Fee Transmittal and Extension of Time

DRC:n FIRST CLASS MAIL *January 5, 1996* by njw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Lin, et al.	Group Art Unit:	1812
Serial No.:	08/182,183	Examiner:	Marianne P. Allen
Filed:	May 23, 1994		
For:	GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR		
Docket No.:	SYNE-225-E (SYNE225/C4-US)		

TRANSMITTAL OF RESPONSE TO OFFICE ACTION


Assistant Commissioner of Patents  
Washington, D. C. 20231

Sir:

Enclosed herewith are 1) the Response to the Office Action dated September 7, 1995 (i.e., Paper Number 20); 2) sequence listing in both computer readable format and in printed form and attorney statement pursuant to 37 C.F.R. 1.821(f); and 3) fee transmittal and petition for extension of time under 37 C.F.R. 1.136(a).

The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account 01-0519.

Respectfully submitted



Daniel R. Curry  
Attorney for Applicants  
Registration No. 32,727  
Phone: (805) 447-8102  
Date: January 5, 1996

Please send all future correspondence to:  
U.S. Patent Operations/DRC  
M/S 10-1-B  
AMGEN INC.  
Amgen Center  
1840 Dehavilland Drive  
Thousand Oaks, California 91320-1789

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

January 5, 1996

Date



Nola J. Wyeth